These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30216039)

  • 1. DARK Classics in Chemical Neuroscience: Ibogaine.
    Wasko MJ; Witt-Enderby PA; Surratt CK
    ACS Chem Neurosci; 2018 Oct; 9(10):2475-2483. PubMed ID: 30216039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibogaine in the treatment of substance dependence.
    Brown TK
    Curr Drug Abuse Rev; 2013 Mar; 6(1):3-16. PubMed ID: 23627782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.
    Wei D; Maisonneuve IM; Kuehne ME; Glick SD
    Brain Res; 1998 Aug; 800(2):260-8. PubMed ID: 9685673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.
    Corkery JM
    Prog Brain Res; 2018; 242():217-257. PubMed ID: 30471681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of novel medications for drug addiction. The legacy of an African shrub.
    Glick SD; Maisonneuve IM
    Ann N Y Acad Sci; 2000; 909():88-103. PubMed ID: 10911925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats.
    Glick SD; Kuehne ME; Maisonneuve IM; Bandarage UK; Molinari HH
    Brain Res; 1996 May; 719(1-2):29-35. PubMed ID: 8782860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
    Glick SD; Maisonneuve IM; Szumlinski KK
    Ann N Y Acad Sci; 2000 Sep; 914():369-86. PubMed ID: 11085336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hERG Blockade by Iboga Alkaloids.
    Alper K; Bai R; Liu N; Fowler SJ; Huang XP; Priori SG; Ruan Y
    Cardiovasc Toxicol; 2016 Jan; 16(1):14-22. PubMed ID: 25636206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of antiaddictive actions of ibogaine.
    Glick SD; Maisonneuve IS
    Ann N Y Acad Sci; 1998 May; 844():214-26. PubMed ID: 9668680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-addiction drug ibogaine and the heart: a delicate relation.
    Koenig X; Hilber K
    Molecules; 2015 Jan; 20(2):2208-28. PubMed ID: 25642835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug.
    Popik P; Layer RT; Skolnick P
    Pharmacol Rev; 1995 Jun; 47(2):235-53. PubMed ID: 7568327
    [No Abstract]   [Full Text] [Related]  

  • 12. DARK Classics in Chemical Neuroscience: Psilocybin.
    Geiger HA; Wurst MG; Daniels RN
    ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration.
    Pace CJ; Glick SD; Maisonneuve IM; He LW; Jokiel PA; Kuehne ME; Fleck MW
    Eur J Pharmacol; 2004 May; 492(2-3):159-67. PubMed ID: 15178360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ibogaine - structure, influence on human body, clinical relevance].
    Zdrojewicz Z; Kuszczak B; Olszak N
    Pol Merkur Lekarski; 2016 Jul; 41(241):50-55. PubMed ID: 27734823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How toxic is ibogaine?
    Litjens RP; Brunt TM
    Clin Toxicol (Phila); 2016; 54(4):297-302. PubMed ID: 26807959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats.
    Rho B; Glick SD
    Neuroreport; 1998 May; 9(7):1283-5. PubMed ID: 9631413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibogaine acts at the nicotinic acetylcholine receptor to inhibit catecholamine release.
    Mah SJ; Tang Y; Liauw PE; Nagel JE; Schneider AS
    Brain Res; 1998 Jun; 797(1):173-80. PubMed ID: 9630615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents.
    Kuehne ME; He L; Jokiel PA; Pace CJ; Fleck MW; Maisonneuve IM; Glick SD; Bidlack JM
    J Med Chem; 2003 Jun; 46(13):2716-30. PubMed ID: 12801235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders.
    Straub CJ; Rusali LE; Kremiller KM; Riley AP
    J Med Chem; 2023 Jan; 66(1):107-121. PubMed ID: 36440853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ibogaine medical subculture.
    Alper KR; Lotsof HS; Kaplan CD
    J Ethnopharmacol; 2008 Jan; 115(1):9-24. PubMed ID: 18029124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.